Found: 21
Select item for more details and to access through your institution.
BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study.
- Published in:
- European Journal of Haematology, 2020, v. 105, n. 2, p. 164, doi. 10.1111/ejh.13420
- By:
- Publication type:
- Article
Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection.
- Published in:
- Haemophilia, 2020, v. 26, n. 3, p. e145, doi. 10.1111/hae.13973
- By:
- Publication type:
- Article
Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin.
- Published in:
- Pharmaceutical Research, 2021, v. 38, n. 3, p. 381, doi. 10.1007/s11095-021-02994-1
- By:
- Publication type:
- Article
Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
- Published in:
- Journal of Thrombosis & Thrombolysis, 2020, v. 50, n. 1, p. 1, doi. 10.1007/s11239-020-02073-z
- By:
- Publication type:
- Article
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
- Published in:
- Journal of Thrombosis & Thrombolysis, 2020, v. 50, n. 1, p. 12, doi. 10.1007/s11239-020-02078-8
- By:
- Publication type:
- Article
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation.
- Published in:
- Journal of Thrombosis & Thrombolysis, 2020, v. 50, n. 1, p. 20, doi. 10.1007/s11239-020-02077-9
- By:
- Publication type:
- Article
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 11, p. 1639, doi. 10.1007/s40262-023-01282-y
- By:
- Publication type:
- Article
Meta-analysis for diagnostic accuracy studies: a new statistical model using beta-binomial distributions and bivariate copulas.
- Published in:
- Statistics in Medicine, 2014, v. 33, n. 1, p. 17, doi. 10.1002/sim.5909
- By:
- Publication type:
- Article
Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis.
- Published in:
- Drugs in R&D, 2023, v. 23, n. 3, p. 221, doi. 10.1007/s40268-023-00427-5
- By:
- Publication type:
- Article
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 4, p. 1, doi. 10.1111/cts.13784
- By:
- Publication type:
- Article
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 2, p. 266, doi. 10.1002/cpt.2873
- By:
- Publication type:
- Article
Evaluation of covariate effects in item response theory models.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 5, p. 812, doi. 10.1002/psp4.13120
- By:
- Publication type:
- Article
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 8, p. 890, doi. 10.1002/psp4.12663
- By:
- Publication type:
- Article
Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2019, v. 8, n. 12, p. 894, doi. 10.1002/psp4.12464
- By:
- Publication type:
- Article
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2019, v. 8, n. 11, p. 805, doi. 10.1002/psp4.12444
- By:
- Publication type:
- Article
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2018, v. 7, n. 5, p. 309, doi. 10.1002/psp4.12288
- By:
- Publication type:
- Article
Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
- Published in:
- Annals of Hematology, 2020, v. 99, n. 11, p. 2689, doi. 10.1007/s00277-020-04280-3
- By:
- Publication type:
- Article
Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
- Published in:
- 2019
- By:
- Publication type:
- Journal Article